United States· US:0006-5331_114cd6ad-9203-4034-b390-3e0901e064a4
WELIREG
A belzutifan product containing belzutifan, registered in United States by Merck Sharp & Dohme LLC. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Belzutifan is registered in 14 of 19 countries.
Countries holding a registration under ATC L01XX74 (belzutifan), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Belzutifan · ATC L01XX74
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of belzutifan costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Belzutifan · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- FR France$0.54
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- BELZUTIFAN
- Manufacturer
- Merck Sharp & Dohme LLC
- Country
- United States (US)
- ATC code
- L01XX74
- ATC class
- Belzutifan
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 26, 2026
Packs & prices · 6
- ndc11000653310190 TABLET, FILM COATED in 1 BOTTLE (0006-5331-01)
- ndc1100065331581 BOTTLE in 1 CARTON (0006-5331-58) / 90 TABLET, FILM COATED in 1 BOTTLE
- ndc1100065331591 BOTTLE in 1 CARTON (0006-5331-59) / 90 TABLET, FILM COATED in 1 BOTTLE
- ndc110006-5331-01
- ndc110006-5331-58
- ndc110006-5331-59
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Belzutifan in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandWelireg 40 mg, FilmtablettenMSD Merck Sharp & Dohme AG
- CzechiaWELIREGMerck Sharp & Dohme B.V., Haarlem
- SpainWELIREG 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Sharp & Dohme B.V.
- FinlandWELIREGMerck Sharp & Dohme B.V.
- FranceWELIREG 40 mg, comprimé pelliculéMERCK SHARP & DOHME (PAYS-BAS)
- IrelandWELIREG 40 mg film-coated tabletsMerck Sharp & Dohme BV,
- IcelandWeliregMerck Sharp & Dohme B.V.*
- NetherlandsWELIREG 40 mg filmomhulde tablettenMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Welireg
- Liechtenstein · Welireg
- Norway · Welireg
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/72c48bfa-d449-435f-a174-443e16491b95 GET /v1/drugs/72c48bfa-d449-435f-a174-443e16491b95?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "40",
"substance": "BELZUTIFAN",
"productndc": "0006-5331",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA215383",
"marketing_category": "NDA"
}See everything about belzutifan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.